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Introduction: We investigated EGFR and KRAS alterations among
atypical adenomatous hyperplasia and small lung adenocarcinomas
with bronchioloalveolar features to understand their role during
multistage pathogenesis.
Methods: Sixty lesions measuring 2 cm or less were studied,
including 38 noninvasive lesions (4 atypical adenomatous hyperpla-
sias, 19 Noguchi type A and 15 type B) and 22 invasive lesions (type
C) based on the World Health Organization classification and
Noguchi’s criteria. EGFR and KRAS mutations were examined using
PCR-based assays. EGFR copy number was evaluated using fluo-
rescence in situ hybridization.
Results: EGFR and KRAS mutations were found in 26 (43.3%) and
5 (8.3%) lesions, respectively. Increased EGFR copy number status
was identified in 10 lesions (16.7%), both mutant and wild type.
EGFR or KRAS mutations were present in 39.5% and 7.9% (respec-
tively) of noninvasive lesions and 50% or 9.1% (respectively) of
invasive lesions. EGFR copy number was increased in 7.9% and
31.8% of noninvasive and invasive lesions (P 0.029). Multivariate
analysis revealed that increased EGFR copy number was the only
significant factor to associate with invasive lesions (P  0.035).
Conclusions: EGFR and KRAS mutations occur early during the
multistage pathogenesis of peripheral lung adenocarcinomas. By
contrast, increased EGFR copy number is a late event during tumor
development and plays a role in the progression of lung adenocar-
cinoma independent of the initiating molecular events.
Key Words: Multistage pathogenesis, EGFR, KRAS, Mutation,
Amplification.
(J Thorac Oncol. 2008;3: 340–347)
Adenocarcinomas of the lung represent a heterogeneousgroup of tumors. The major subtypes identified by the
World Health Organization (WHO) consist of bronchioloalveo-
lar carcinoma (BAC), acinar, papillary, or solid with mucin.1,2
However, the majority of tumors consist of mixtures of two or
more subtypes. BAC is defined as a noninvasive tumor that has
lepidic spread, i.e., replacement of the bronchiolar or alveolar
epithelium by tumor cells. The WHO also recognized a periph-
eral lesion, atypical adenomatous hyperplasia (AAH), as a pre-
cursor lesion for BAC. These findings indicate a multistage
progression model for most peripheral adenocarcinomas—
AAHs giving rise to noninvasive BAC tumors, which later
become invasive (mixed histology adenocarcinomas having a
BAC component). In 1995, Noguchi and colleagues developed
an independent classification for small peripheral adenocarcino-
mas (2 cm in size) consisting of six tumor subtypes.3 Types A,
B, and C consisted entirely or predominantly of a BAC compo-
nent (“replacement tumors”). Types A and B consisted of BAC
tumors without (type A) or with (type B) areas of alveolar
collapse and subsequent fibrosis. Among these two subtypes,
nodal metastases were never present, and these tumors had a
100% 5-year survival if they were small (2 cm) and were
completely resected. Type C tumors were BAC tumors with foci
or fibroblastic proliferation. 28% of these tumors had lymph
node metastases and the 5-year survival was 74.8%, similar to
the average survival rate for small adenocarcinomas as a group.
For practical purposes, we can regard the Noguchi type A and B
tumors as the equivalent of WHO BAC subtype and Noguchi
type C tumors as the equivalent of WHO mixed (i.e., invasive)
tumors having a prominent BAC component. Certain molecular
changes are characteristic of adenocarcinomas of the lung. These
include mutations within the tyrosine kinase domain of the
epidermal growth factor receptor (EGFR) gene, amplifications
of the EGFR gene, and activating mutations of the KRAS gene.
EGFR mutations, especially deletions in exon 19 and L858R
point mutations in exon 21, target lung cancers arising in certain
subsets: never smoker status, adenocarcinoma histology, female
gender, and East Asian ethnicity.4–9 The mutations have been
reported to be more frequent in adenocarcinomas having BAC
features.4,6,10 The KRAS gene is a member of the ras family of
oncogenes, and is located downstream of EGFR in the signaling
pathway of the EGFR surface receptor. KRAS mutations are
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found in 10 to 30% in non-small cell lung cancer (NSCLC),
especially adenocarcinomas, and over 90% of the mutations
occurred in codon 12, occasionally in codon 13, and rarely in
codon 61.11–15 Although both KRAS and EGFR mutations target
lung adenocarcinomas, the former are associated with ever
smoker status, male gender, and non-East Asian ethnicity.16,17
Thus, the two mutations seem to target different subpopula-
tions and their presence may indicate alternative methods of
adenocarcinoma pathogenesis.18 Of interest, EGFR and KRAS
mutations may be present in AAH and in nonmalignant
peripheral airways adjacent to cancers.19–21 Indeed, KRAS mu-
tations or EGFR mutations in exon 19 or 21 cause multifocal
BAC in mouse models.22,23 Increased copy number of EGFR, as
assessed by fluorescence in situ hybridization (FISH) assay, was
associated with lymph node metastasis, more advanced patho-
logic stage, and poor prognosis.24–28 This alteration has been
described in NSCLC, especially adenocarcinomas, and may
occur in mutant- or wild-type tumors.26,27 Furthermore, the three
molecular changes discussed above may influence tumor re-
sponse to small molecular weight tyrosine kinase inhibitors
(TKIs) such as erlotinib and gefitinib. Both activating EGFR
mutations and increased gene copy number are associated
with good clinical outcome of EGFR-TKIs treatment,27,29,30
while KRAS mutations are associated with clinical resistance.30,31
To elucidate the roles of EGFR or KRAS mutations and
increased EGFR copy number in the multistage pathogenesis
of peripheral adenocarcinomas, we studied these molecular
changes in small tumors having BAC features.
PATIENTS AND METHODS
Patients and Materials
During October 1997 to April 2005, 838 patients with
NSCLC underwent pulmonary operations at Department of
Cancer and Thoracic Surgery, Okayama University Hospital.
Of these, 48 patients had lung adenocarcinoma (or AAH lesions)
measuring 2 cm or less in greatest dimension and who had not
received chemotherapy, radiotherapy, or targeted therapy
before surgery. Among them, single lesions were resected
from 39 patients. There were 8 patients who had 19 synchro-
nous lesions in their resected specimens (2–4 lesions per
resection) and one patient who had 2 metachronous lesions
resected over a 6-year interval. Details of the synchronous
and metachronous lesions, as defined by the criteria of Mar-
tini and Melamed,32 are presented in Table 1. Thus, from the
48 patients, a total of 60 lesions were available for study.
Institutional review board permission and informed consent
were obtained from all 48 patients for genetic analyses.
The following clinical factors were evaluated: age, sex,
smoking status, and tumor size. All 60 cases were categorized
into four histologic subtypes based on WHO classification
and Noguchi’s criteria1,3; AAH (n 4), type A (n 19), type
B (n 15), and type C (n 22). Because AAH is considered
as a preinvasive lesion and Noguchi types A and B represent
the noninvasive BAC (as defined by the WHO classification),
we combined three categories and compared their findings
with those present in Noguchi type C tumors (mixed subtype
TABLE 1. Genetic Alternations in 21 Multiple Lesions of Nine Patients
Patient
Age
(yr) Sex
Smoking
Status
Tumor
Size (mm)
Histological
Classification
EGFR
Mutation
EGFR
FISH
KRAS
Mutation
1 49 M Never 16 Type C Wt N Wt
55 16 Type C Wt P Wt
2 67 F Never 9 Type A Wt N Wt
10 Type C Wt N Wt
3 77 F Never 9 Type A L858R P Wt
9 Type A Wt N Wt
10 Type A Wt N Wt
9 Type C L858R N Wt
4 68 F Never 5 AAH L858R N Wt
18 Type C L858R P Wt
5 72 M Ever 10 Type B Wt P Wt
15 Type C Wt P Wt
6 67 F Never 15 Type A Wt N C12
20 Type A ex19 dels N Wt
7 61 F Never 4 AAH Wt N Wt
10 Type A Wt N Wt
8 65 M Ever 5 AAH Wt N Wt
20 Type A Wt N Wt
18 Type B L858R N Wt
9 70 F Never 11 Type A L858R N Wt
20 Type B L858R N Wt
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; M, male; F, female; AAH, atypical adenomatous hyperplasia; types
A, B, and C, classified according to Noguchi’s criteria; Wt, wild type; L858R; exon 21 L858R point mutation; ex19 dels, exon 19 deletions; N, negative;
P, positive; C12, codon 12 point mutation; patient number 1 is a metachronous multiple case and patients number 2–7 are synchronous multiple cases.
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invasive adenocarcinomas with BAC component by the
WHO classification). We excluded the other types of small
adenocarcinomas (Noguchi types D, E, and F, WHO acinar,
papillary, or solid subtypes) from this study as a convincing
multistage pathogenesis has not been defined for these tumors.
DNA Extraction and Mutation Analyses of EGFR
and KRAS Genes
For all 60 lesions that were formalin fixed and paraffin
embedded, DNAs were isolated by DEXPAT (TaKaRa,
Shiga, Japan) following the manufacturer’s instructions.
Among them, DNAs of 17 frozen lesions were also isolated
by digestion with proteinase K, followed by phenol-chloro-
form (1:1) extraction and ethanol precipitation from frozen
specimen.33 EGFR mutations examination was limited to
exon 19 deletions and exon 21 L858R point mutations by two
methods: mutant-enriched or nonenriched PCR assays as
described previously.34 Mutant-enriched PCR is a two-step
PCR with intermittent restriction digestion to eliminate wild-
type genes selectively, thus enriching the mutated genes at
high sensitively. Nonenriched PCR is a one-step PCR without
intermittent restriction digestion. The product of the amplifi-
cation in the both methods was analyzed on 12% polyacryl-
amide gel electrophoresis (PAGE) via ethidium bromide
staining. The common deletions of exon 19 were distinguished
from the wild type based on PCR product length polymorphisms
using 12% PAGE. For exon 21, Sau96I digestion, which could
specifically digest the mutant type, was done before 12%
PAGE. Mutant-enriched PCR assay can detect one mutant
out of 2  103 wild-type genes. On the other hand, nonen-
riched PCR assay can detect one mutant of 10 wild-type genes.
We analyzed KRAS mutations using a PCR assay with restric-
tion digestion, followed by 12% PAGE, which was detectable of
codon 12 point mutation based on the report by Kahn et al.35
These methods were predicted to detect about 85% of
EGFR tyrosine kinase domain mutations8,36 and about 90% of
KRAS mutations.11,12,37
EGFR Copy Number Analysis by FISH Assay
Paraffin-embedded tissues of all 60 specimens were
studied by FISH assay. A dual-color FISH assay was per-
formed using the LSI EGFR spectrumOrange/CEP7 spec-
trumGreen probe (Vysis, Downers Grove, IL) following man-
ufacturer’s instructions. At least 100 nonoverlapping inter
phase nuclei per slide were scored by two independent
observers (I.S., S.J.). All cases were classified into six FISH
strata according to the criteria of Cappuzzo et al.27 Using their
criteria, samples scored as having disomy, low trisomy, high
trisomy, or low polysomy were classified as “FISH negative,”
whereas samples scored as high polysomy or gene amplifi-
cation were categorized as “FISH positive.”
Statistical Analyses
The differences of significance among categorized
groups were compared using 2 or Fisher exact test tests as
appropriate for univariate analyses. Logistic regression mod-
els using all variables were used to further explore observed
differences and to identify baseline factors that may indepen-
dently correlate with histologic classification. All data were
analyzed with StatView 5.0 Program for Windows (SAS
Institute Inc., Cary, NC). All statistical tests were two-sided
and probability values 0.05 were defined as being statisti-
cally significant.
RESULTS
Patient Characteristics
The details of patient characteristics are shown in Table
2. Pathologic examination of the 60 lesions from 48 patients
indicated that each of the 60 lesions was a discreet presum-
ably independently arising lesion. Of the 48 patients (9 of
whom had multiple lesions), 31 had one or more noninvasive
lesions whereas 17 had only invasive lesion. At the time of
analysis, only one patient with an invasive cancer (which was
EGFR FISH positive, but wild type for EGFR and KRAS
mutations) had died of recurrent lung cancer 3 years after
diagnosis. The mean follow-up duration of the 47 survivors
were 35.0 months (range, 8.4–102.9 months). Thus, the
relationship between survival and clinicopathologic or mo-
lecular features could not be analyzed.
Because some resected samples contained lesions of
both noninvasive and invasive categories, we chose to present
the data from the 60 individual lesions, rather than from 48
individual patients.
Somatic Alterations of EGFR and KRAS Genes
Details of genetic and clinical data are shown in Tables
3 and 4. Among 60 lesions, we detected EGFR mutations in
26 lesions (43.3%), 15 as exon 19 deletions and 11 as L858R
point mutation, with complete concordance of results by
nonenriched and mutant-enriched PCR assays. KRAS codon
12 mutations were detected in 5 of 60 lesions (8.3%). Only
one noninvasive cancer had mutations in both genes. We also
confirmed the mutational data of EGFR and KRAS genes
TABLE 2. Characteristics of 60 Lesions in 48 Patients
Variables No.
Age (yr) Median 65 (range, 41–84)
65 28
65 32
Sex
Male 23
Female 37
Smoking history
Never 37
Ever 23
Tumor size (mm) Median 12 (range 4–20)
12 33
12 27
Histology
AAH 4
Type A 19
Type B 15
Type C 22
Never, never smokers; Ever, ever smokers; AAH, atypical adenomatous hyperpla-
sia; types A, B and C, histologic subtypes defined based on Noguchi’s criteria.
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among 17 lesions whose DNAs were extracted from both
paraffin-embedded samples and frozen samples. No discrep-
ancies were identified from the analyses of these two differ-
ently handled DNA specimens.
For EGFR copy number, 50 lesions (83.3%) were
scored as FISH negative (disomy in 14 lesions, low trisomy
in 19, high trisomy in 7, and low polysomy in 10), and 10
lesions (16.7%) were scored as FISH positive (high polysomy
in 9 and amplification in 1). Four lesions had both EGFR
mutation and FISH positivity and one lesion had both KRAS
mutation and FISH positivity. The other 4 lesions as FISH
positive were wild type for both genes. Thus, FISH positivity
showed no selectivity for EGFR mutation positive (15.4%),
KRAS mutation positive (20.0%), or wild type (16.7%) le-
sions. Example of FISH results are shown in Figure 1.
Synchronous and Metachronous Tumors
Twenty-one synchronous or metachronous lesions were
found in nine patients (Table 1), consistent with the field
cancer theory.32 One of these patients had metachronous
lesions that arose in the opposite lungs 6 years apart (patient
1). We regarded these as independent primary tumors. Eight
other patients had 2, 3, or 4 synchronous lesions (patients
TABLE 3. The Correlation Between Histologic Subsets and Clinical and Genetic Factors
Variables Subset
Total
No. (%)
Noninvasive Group
Invasive Group
Type C
(n  22)
No. (%) P*
AAH
(n  4)
No. (%)
Type A
(n  19)
No. (%)
Type B
(n  15)
No. (%)
Total
(n  38)
No. (%)
Age (yr) 65 28 (46.7) 2 (50.0) 9 (47.4) 7 (46.7) 18 (47.4) 10 (45.5) 0.89
65 32 (53.3) 2 (50.0) 10 (52.6) 8 (53.3) 20 (52.6) 12 (54.5)
Sex Male 23 (38.3) 2 (50.0) 3 (15.8) 9 (60.0) 14 (36.8) 9 (40.9) 0.75
Female 37 (61.7) 2 (50.0) 16 (84.2) 6 (40.0) 24 (63.2) 13 (59.1)
Smoking status Never 37 (61.7) 2 (50.0) 14 (73.7) 6 (40.0) 22 (57.9) 15 (68.2) 0.43
Ever 23 (38.3) 2 (50.0) 5 (26.3) 9 (60.0) 16 (42.1) 7 (31.8)
Tumor size (mm) 12 33 (55.0) 4 (100) 13 (68.4) 8 (53.3) 25 (65.8) 8 (36.4) 0.027
12 27 (45.0) 0 (0) 6 (31.6) 7 (46.7) 13 (34.2) 14 (63.6)
EGFR gene Mutant 26 (43.3) 1 (25.0) 7 (36.8) 7 (46.7) 15 (39.5) 11 (50) 0.43
Wild 34 (56.7) 3 (75.0) 12 (63.2) 8 (53.3) 23 (60.5) 11 (50)
FISH positive 10 (16.7) 0 (0.0) 1 (5.3) 2 (13.3) 3 (7.9) 7 (31.8) 0.029
FISH negative 50 (83.3) 4 (100) 18 (94.7) 13 (86.7) 35 (92.1) 15 (68.2)
KRAS Mutant 5 (8.3) 0 (0.0) 2 (10.5) 1 (6.7) 3 (7.9) 2 (9.1) 1
Mutation Wild 55 (91.7) 4 (100) 17 (89.5) 14 (93.3) 35 (92.1) 20 (90.9)
AAH, atypical adenomatous hyperplasia; types A, B and C, histological subtypes defined based on Noguchi’s criteria; Never; never smokers; Ever; ever smokers; EGFR,
epidermal growth factor receptor; FISH, fluorescence in situ hybridization.
*P value was evaluated by non-invasive group versus invasive group.
TABLE 4. Correlation Between Genetic Alteration and Clinical Factors
Variables
EGFR Mutation EGFR FISH KRAS Mutation
Mutant
(n  26)
n (%)
Wild
(n  34)
n (%) P
Positive
(n  10)
n (%)
Negative
(n  50)
n (%) P
Mutant
(n  5)
n (%)
Wild
(n  55)
n (%) P
Age (yr)
65 (n  28) 12 (42.9) 16 (57.1) 0.94 2 (7.1) 26 (92.9) 0.088 3 (10.7) 25 (89.3) 0.66
65 (n  32) 14 (43.8) 18 (56.2) 8 (25.0) 24 (75.0) 2 (6.3) 30 (93.7)
Sex
Male (n  23) 7 (30.4) 16 (69.6) 0.11 6 (26.1) 17 (73.9) 0.16 3 (13.0) 20 (87.0) 0.36
Female (n  37) 19 (51.4) 18 (48.6) 4 (10.8) 33 (89.2) 2 (5.4) 35 (94.6)
Smoking status
Never (n  37) 18 (48.6) 19 (51.4) 0.29 5 (13.5) 32 (86.5) 0.49 2 (5.4) 35 (94.6) 0.36
Ever (n  23) 8 (34.8) 15 (65.2) 5 (21.7) 18 (78.3) 3 (13.0) 20 (87.0)
Tumor size
12 mm (n  33) 10 (30.3) 23 (69.7) 0.024 5 (15.2) 28 (84.8) 0.74 1 (3.0) 32 (97.0) 0.16
12 mm (n  27) 16 (59.3) 11 (40.7) 5 (18.5) 22 (81.5) 4 (14.8) 23 (85.2)
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; Never, never smokers; Ever, ever smokers.
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FIGURE 1. Representative examples of fluorescence in situ hybridization (FISH) with epidermal growth factor receptor
(EGFR) (red signals) and chromosome 7 (green signals) probes. Case 1: One Noguchi type A lesion (left-top, H&E) with EGFR
L858R point mutation (left-bottom) indicates EGFR FISH negative (Disomy) (right); Mean values of chromosome 7 and EGFR
copy numbers are 2.19  0.61 and 2.22  0.69 (mean  SD) per 100 nuclei, respectively. The percentage of 2 copies of
EGFR gene is 90% and the ratio of EGFR gene to chromosome 7 is 1.00. Case 2: One Noguchi type C lesion (left-top, H&E)
with EGFR exon 19 deletions (left-bottom) indicates EGFR FISH positive (high polysomy) (right); Mean values of chromosome
7 and EGFR copy numbers are 3.58  1.30 and 3.36  1.19 (mean  SD) per 100 nuclei, respectively. The percentage of 4
copies of EGFR gene is 53% and the ratio of EGFR gene to chromosome 7 is 1.07.
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2–9). Of these, 4 patients (patients 2–5) had individual lesions
having either noninvasive or invasive components.
Evaluation of Clinical and Genetic Factors
According to Histologic Difference
We investigated the relationship between clinical and
genetic factors by each of the two histologic subsets (Table 3).
By univariate analyses of the clinical factors, larger tumor size
was significantly associated with invasive tumor (p 0.027). Of
the genetic factors, EGFR or KRAS mutations were present in 15
(39.5%) or 3 (7.9%) of 38 noninvasive lesions and 11 (50%) or
2 (9.1%) of 22 invasive lesions; however, these differences were
not significant. By contrast, increased EGFR copy number was
found in 3 (7.9%) of noninvasive lesions and 7 (31.8%) of
invasive lesions (p  0.029).
By multivariate analyses, FISH positivity was the only
factor that was significantly associated with invasive tumors
(OR  6.5, 95% confidence interval: 1.14–37.3, p  0.035).
DISCUSSION
Our study reveals important differences in the sequen-
tial appearance of molecular changes during multistage
pathogenesis of small peripheral adenocarcinomas having a
BAC component. EGFR mutations were found in all four
categories of lesions examined including an AAH. KRAS
mutations, while not detected in the small number of AAH
lesions examined, were present in noninvasive and invasive
carcinomas of Noguchi types A, B, and C. There were no
significant differences in the frequencies of these two muta-
tion types between the pathologic types. By contrast, we
found a significant difference for EGFR gene FISH status,
with FISH positivity being significantly more frequent in the
invasive group of lesions (type C).
Our findings regarding these mutational changes are
consistent with the published literature. Both KRAS and
EGFR mutations have been described in AAH lesions,20,37,38
and EGFR mutations have been found in the nonmalignant
peripheral airways in the vicinity of invasive peripheral
adenocarcinomas,21 indicating that mutations of both genes
are early events that play a role in tumor initiation.
Recent reports demonstrate that the KRAS mutations
are more frequent in BACs of the mucinous subtype whereas
EGFR mutations are more frequent in the nonmucinous
subtype.10,39 In our 60 lesions, 59 lesions (98.3%) were
nonmucinous type of BACs, and only one lesion was a
mucinous BAC without genetic alterations. Furthermore, we
focused on small adenocarcinomas with BAC components,
which are well-known to correlate with female, never smok-
ing status.40 KRAS mutations are also associated with ever
smoker status, male gender, and non-East Asian ethnicity.16,17
These findings support the lower frequency of KRAS muta-
tions in this cohort.
We found one rare case harboring both EGFR and KRAS
mutations, who is a 61-year-old man with heavy smoking
history (50 packs per year). This noninvasive and nonmuci-
nous lesion (Noguchi type B) has KRAS codon 12 point
mutation and EGFR L858R point mutation without EGFR
FISH positivity (low trisomy). As mentioned above, KRAS
mutations are significantly frequent in males and ever smok-
ers whereas EGFR mutations in females and never smokers
and BACs, especially in the nonmucinous type.10,16,17,39
However, Shigematsu et al. also indicated that EGFR muta-
tions could be detected in 10% of males and 14% of ever
smokers.16 These findings might explain this rare case, which
has both characteristics of EGFR and KRAS mutations.
Our current study clearly revealed that increased copy
number of the EGFR gene seems to be a progression event
independent from the initial alterations, being more than four
times more frequent in invasive lesions than in noninvasive
lesions. These differences are also significant even if the four
AAH lesions are removed from the analysis (p  0.039).
Patient number 4 (Table 1) is of particular interest. She had
synchronous noninvasive AAH and invasive (Noguchi type
C) lesions. Although both lesions had identical (L858R)
EGFR mutations, the invasive cancer was FISH positive,
whereas the AAH was FISH negative, providing support for
our concept that the activating mutations occur early in
pathogenesis, while FISH positivity is a late event associated
with advanced (invasive) cancers. Our findings are consistent
FIGURE 2. Putative multiple molecular pathways to periph-
eral lung adenocarcinomas. Adenocarcinomas represent a het-
erogenous mixture, and may arise from peripheral or central
airways. Adenocarcinomas arising from the peripheral airways
often contain a bronchioloalveolar component. From work pre-
sented in this report and from the published literature, it would
appear that there are at least three early or initiating sets of
events. Pathway 1, more frequently seen in never or light
smokers, involves activating mutations of the epidermal growth
factor receptor (EGFR) gene. Pathway 3, almost limited to ever
smokers, involves activating mutations of the KRAS gene. Path-
way 1 targets females and East Asian ethnicity, whereas path-
way 3 targets males and non-East Asian ethnicity. However, the
combined frequencies of these mutations (on a worldwide ba-
sis) are about 50% of adenocarcinomas. Thus, one or more
alternative pathways (pathway 2) must use other initiating
events. From data presented in this report, it would appear
that increased EGFR copy number is a late (progression) event,
and that targets tumors irrespective of the initiating events.
Figure modified from Gazdar AF, Shigematsu H, Herz J, et al.
Mutations and addiction to EGFR: the Achilles ‘heal’ of lung
cancers? Trends Mol Med 2004;10:481–486; and Wistuba II,
Gazdar AF. Lung cancer preneoplasia. Annu Rev Pathol Mech Dis
2006;1:331–348.
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with recent reports that describe EGFR mutations preceding
amplification, with amplification favoring the mutant allele.41
Our findings clearly demonstrate that FISH positivity occurs
as frequently in mutant- and wild-type tumors, and that these
two events associated with response to tyrosine kinase inhib-
itors occur independently of each other.26,42
Gazdar et al. have proposed that peripheral lung ade-
nocarcinomas arise via three or more pathways.18 In smokers,
activation of the KRAS pathway via mutations occurs,
whereas in nonsmokers, there is upstream activation of the
EGFR pathway via activating mutations. As these changes
only account for about 50% of lung adenocarcinomas, other
initiating events may also contribute to pathogenesis. Based
on our finding, a hypothesis of putative molecular pathways
to peripheral lung adenocarcinomas is shown in Figure 2.
Although EGFR and KRAS mutations are early, possibly
initiating events for subsets of adenocarcinomas, increased
copy number of the EGFR gene seems to be a late or progression
event and targets adenocarcinomas irrespective of the initiat-
ing events. However, our sample size is not large and further
investigation is warranted to confirm our hypothesis.
Our findings suggest that increased gene copy number
may be a relatively late event in tumor pathogenesis, and that
the original molecular status of the tumor may not accurately
reflect the response to TKIs of a recurrent or metastatic lesion.
The recognition that molecular events are dynamic and pro-
gressive necessitates retesting advanced or recurrent tumors
to determine optimal, individualized targeted therapies.
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